A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?

Vasc Health Risk Manag · 2014 · PMC4149394 · PMID 25187724

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

a nonsignificant trendP =0.051so close (0.05 < p ≤ 0.1)

There was a nonsignificant trend toward reduced risk of mortality with dabigatran 150 mg versus warfarin ( P =0.051); however, this trend did not occur with the dabigatran 110 mg twice daily dosage ( P =0.13).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.